F.D.A. Sharply Limits Approval for Drug Linked to Two Teen Deaths

nytimes.com/2025/11/14/health/fda-muscular-dystrophy-sarepta.html

The drug Elevidys has been central to the business model of Sarepta Therapeutics, a publicly traded company that is worth about $2 billion.

This story appeared on nytimes.com, 2025-11-14 20:23:01.
The Entire Business World on a Single Page. Free to Use →